Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.
| Revenue (Most Recent Fiscal Year) | $67.64M |
| Net Income (Most Recent Fiscal Year) | $-116.04M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.04 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.40 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -153.41% |
| Net Margin (Trailing 12 Months) | -149.57% |
| Return on Equity (Trailing 12 Months) | -79.83% |
| Return on Assets (Trailing 12 Months) | -26.65% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.29 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.29 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.38 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.06 |
| Earnings per Share (Most Recent Fiscal Year) | $-5.48 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.54 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 21.38M |
| Free Float | 18.41M |
| Market Capitalization | $131.68M |
| Average Volume (Last 20 Days) | 0.11M |
| Beta (Past 60 Months) | 0.81 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 13.89% |
| Percentage Held By Institutions (Latest 13F Reports) | 94.99% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |